Behçet's disease (BD) is a chronic inflammatory and multisystemic autoimmune disease of unknown etiology. Due to the lack of a specific test for BD, its diagnosis is very difficult and therapeutic options are limited. Induced pluripotent stem cell (iPSC) technology, which provides inaccessible disease-relevant cell types, opens a new era for disease treatment. In this study, we generated BD iPSCs from patient somatic cells and differentiated them into hematopoietic precursor cells (BD iPSC-HPCs) as BD model cells. Based on comparative transcriptome analysis using our BD model cells, we identified eight novel BD-specific genes, AGTR2, CA9, CD44, CXCL1, HTN3, IL-2, PTGER4, and TSLP, which were differentially expressed in BD patients compared with healthy controls or patients with other immune diseases. The use of CXCL1 as a BD biomarker was further validated at the protein level using both a BD iPSC-HPC-based assay system and BD patient serum samples. Furthermore, we show that our BD iPSC-HPC-based drug screening system is highly effective for testing CXCL1 BD biomarkers, as determined by monitoring the efficacy of existing anti-inflammatory drugs. Our results shed new light on the usefulness of patient-specific iPSC technology in the development of a benchmarking platform for disease-specific biomarkers, phenotype- or target-driven drug discovery, and patient-tailored therapies.
Get full access to this article
View all access options for this article.
References
1.
SakaneT, TakenoM, SuzukiN and InabaG. (1999). Behcet's disease. N Engl J Med, 341:1284–1291.
2.
VerityDH, WallaceGR, VaughanRW and StanfordMR. (2003). Behcet's disease: from Hippocrates to the third millennium. Br J Ophthalmol, 87:1175–1183.
3.
EglinRP, LehnerT and Subak-SharpeJH. (1982). Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet, 2:1356–1361.
4.
YoshikawaK, KotakeS and MatsudaH. (1996). [Behcet's disease and streptococcal antigens]. Nihon Ganka Gakkai Zasshi, 100:173–180.
5.
ErsoyO, ErsoyR, YayarO, DemirciH and TatlicanS. (2007). H pylori infection in patients with Behcet's disease. World J Gastroenterol, 13:2983–2985.
6.
Eksioglu-DemiralpE, DireskeneliH, KibarogluA, YavuzS, ErgunT and AkogluT. (2001). Neutrophil activation in Behcet's disease. Clin Exp Rheumatol, 19:S19–S24.
7.
CarlettoA, PacorML, BiasiD, CaramaschiP, ZeminianS, BellaviteP and BambaraLM. (1997). Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol, 24:1332–1336.
8.
HamzaouiK, HamzaM and AyedK. (1990). Production of TNF-alpha and IL-1 in active Behcet's disease. J Rheumatol, 17:1428–1429.
9.
AdamB and CalikogluE. (2004). Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behcet's disease. J Eur Acad Dermatol Venereol, 18:318–320.
10.
ZouboulisCC, KatsantonisJ, KettelerR, TreudlerR, KaklamaniE, HornemannS, KaklamanisP and OrfanosCE. (2000). Adamantiades-Behcet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res, 292:279–284.
11.
ToumaZ, FarraC, HamdanA, ShamseddeenW, UthmanI, HouraniH and ArayssiT. (2010). TNF polymorphisms in patients with Behcet disease: a meta-analysis. Arch Med Res, 41:142–146.
12.
MizukiN, MeguroA, OtaM, OhnoS, ShiotaT, KawagoeT, ItoN, KeraJ, OkadaE, et al. (2010). Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet, 42:703–706.
13.
DemirserenDD, CeylanGG, AkogluG, EmreS, ErtenS, ArmanA and MetinA. (2014). HLA-B51 subtypes in Turkish patients with Behcet's disease and their correlation with clinical manifestations. Genet Mol Res, 13:4788–4796.
14.
ZhouQ, HouS, LiangL, LiX, TanX, WeiL, LeiB, KijlstraA and YangP. (2014). MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome. Ann Rheum Dis, 73:170–176.
15.
KontogiannisV and PowellRJ. (2000). Behcet's disease. Postgrad Med J, 76:629–637.
16.
DavatchiF. (2012). Diagnosis/classification criteria for Behcet's disease. Patholog Res Int, 2012:607921.
17.
ZieglerA, KochA, KrockenbergerK and GrosshennigA. (2012). Personalized medicine using DNA biomarkers: a review. Hum Genet, 131:1627–1638.
18.
O'NeillTW, RigbyAS, SilmanAJ and BarnesC. (1994). Validation of the International Study Group criteria for Behcet's disease. Br J Rheumatol, 33:115–117.
19.
KwakJE, SonMY, SonYS, SonMJ and ChoYS. (2015). Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders. Biochem Biophys Res Commun, 457:554–560.
20.
SonMY, ChoiH, HanYM and ChoYS. (2013). Unveiling the critical role of REX1 in the regulation of human stem cell pluripotency. Stem Cells, 31:2374–2387.
21.
SonMY, SeolB, HanYM and ChoYS. (2014). Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency. Hum Mol Genet, 23:1802–1816.
22.
SonMY, KimMJ, YuK, KooDB and ChoYS. (2011). Involvement of neuropeptide Y and its Y1 and Y5 receptors in maintaining self-renewal and proliferation of human embryonic stem cells. J Cell Mol Med, 15:152–165.
23.
SalvagiottoG, BurtonS, DaighCA, RajeshD, SlukvinII and SeayNJ. (2011). A defined, feeder-free, serum-free system to generate in vitro hematopoietic progenitors and differentiated blood cells from hESCs and hiPSCs. PLoS One, 6:e17829.
24.
SonMY, LeeMO, JeonH, SeolB, KimJH, ChangJS and ChoYS. (2016). Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. Exp Mol Med, 48:e232.
25.
SonMY, KimHJ, KimMJ and ChoYS. (2011). Physical passaging of embryoid bodies generated from human pluripotent stem cells. PLoS One, 6:e19134.
26.
OhJH, SonMY, ChoiMS, KimS, ChoiAY, LeeHA, KimKS, KimJ, SongCW and YoonS. (2016). Integrative analysis of genes and miRNA alterations in human embryonic stem cells-derived neural cells after exposure to silver nanoparticles. Toxicol Appl Pharmacol, 299:8–23.
27.
ChoHS, KangJG, LeeJH, LeeJJ, JeonSK, KoJH, KimDS, ParkKH, KimYS and KimNS. (2015). Direct regulation of E-cadherin by targeted histone methylation of TALE-SET fusion protein in cancer cells. Oncotarget, 6:23837–23844.
28.
SonMY, KwakJE, KimYD and ChoYS. (2015). Proteomic and network analysis of proteins regulated by REX1 in human embryonic stem cells. Proteomics, 15:2220–2229.
29.
Aktas CetinE, CosanF, KucuksezerUC, BilgicS, CagatayY, GulA and DenizG. (2013). Behcet's disease: immunological relevance with arthritis of ankylosing spondylitis. Rheumatol Int, 33:733–741.
30.
AgrawalR, IyerJ, ConnollyJ, IwataD and TeohS. (2014). Cytokines and biologics in non-infectious autoimmune uveitis: bench to bedside. Indian J Ophthalmol, 62:74–81.
31.
DuranteW, ChengK and SchaferAI. (1994). Cyclic nucleotide regulation of interleukin-1 beta induced nitric oxide synthase expression in vascular smooth muscle cells. Thromb Res, 75:63–71.
32.
LeekRD, HarrisAL and LewisCE. (1994). Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol, 56:423–435.
33.
EverekliogluC, ErH, TurkozY and CekmenM. (2002). Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm, 11:87–93.
34.
MegeJL, DilsenN, SanguedolceV, GulA, BongrandP, RouxH, OcalL, InancM and CapoC. (1993). Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol, 20:1544–1549.
35.
FiresteinGS. (2003). Evolving concepts of rheumatoid arthritis. Nature, 423:356–361.
36.
HedayatfarA. (2013). Behcet's disease: autoimmune or autoinflammatory?. J Ophthalmic Vis Res, 8:291–293.
37.
OzhanO and SezerK. (2012). Behcet's disease and endocrine system. Patholog Res Int, 2012:827815.
38.
YimCW and WhiteRH. (1985). Behcet's syndrome in a family with inflammatory bowel disease. Arch Intern Med, 145:1047–1050.
39.
ZhouZY, ChenSL, ShenN and LuY. (2012). Cytokines and Behcet's disease. Autoimmun Rev, 11:699–704.
40.
MuftuogluAU, YaziciH, YurdakulS, TuzunY, PazarliH, GungenG and DenizS. (1986). Behcet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol, 25:235–239.
41.
TuranB, GallatiH, ErdiH, GurlerA, MichelBA and VilligerPM. (1997). Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol, 24:128–132.
42.
MaoL, DongH, YangP, ZhouH, HuangX, LinX and KijlstraA. (2008). MALDI-TOF/TOF-MS reveals elevated serum haptoglobin and amyloid A in Behcet's disease. J Proteome Res, 7:4500–4507.
43.
WangX, ZhangMF, XieJ, LiZL and WangP. (2012). Behcet's disease with active uveitis: detection of serum protein biomarkers using MALDI-TOF-MS. Anat Rec (Hoboken), 295:1168–1173.
TavianM, ZhengB, OberlinE, CrisanM, SunB, HuardJ and PeaultB. (2005). The vascular wall as a source of stem cells. Ann N Y Acad Sci, 1044:41–50.
46.
Pineton de ChambrunM, WechslerB, GeriG, CacoubP and SaadounD. (2012). New insights into the pathogenesis of Behcet's disease. Autoimmun Rev, 11:687–698.
47.
ParikhNI and VasanRS. (2007). Assessing the clinical utility of biomarkers in medicine. Biomark Med, 1:419–436.
48.
KatoY and YamamotoT. (2012). Serum levels of GRO-alpha are elevated in association with disease activity in patients with Behcet's disease. Int J Dermatol, 51:286–289.
49.
El-AsrarAM, Al-ObeidanSS, KangaveD, GeboesK, OpdenakkerG, Van DammeJ and StruyfS. (2011). CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology, 216:1004–1009.
50.
MiyakeM, LawtonA, GoodisonS, UrquidiV, Gomes-GiacoiaE, ZhangG, RossS, KimJ and RosserCJ. (2013). Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer, 13:322.
51.
NovitskiySV, PickupMW, GorskaAE, OwensP, ChytilA, AakreM, WuH, ShyrY and MosesHL. (2011). TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov, 1:430–441.
52.
RoyM, RichardJF, DumasA and VallieresL. (2012). CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis. J Neuroinflammation, 9:18.
53.
InoueH and YamanakaS. (2011). The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther, 89:655–661.
54.
GrskovicM, JavaherianA, StruloviciB and DaleyGQ. (2011). Induced pluripotent stem cells—opportunities for disease modelling and drug discovery. Nat Rev Drug Discov, 10:915–929.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
